Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: An analysis of outcome and treatment choices in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO I) and Assessment of the Safety of a New Thrombolytic (ASSENT 2) studies

Circulation

Volumn 103, Issue 7, 2001, Pages 954-960

  Barbash, Gabriel I ^a,h   Birnbaum, Yochai ^b   Bogaerts, Kris ^c   Hudson, Michael ^d   Lesaffre, Emmanuel ^c   Fu, Yuling ^e   Goodman, Shaun ^f   Houbracken, Katrijn ^c   Munsters, Kurt ^c   Granger, Chris B ^d   Pieper, Karen ^d   Califf, Robert M ^d   Topol, Eric J ^g   Van de Werf, Frans ^c  

^a TEL AVIV UNIVERSITY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF ALBERTA   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g LERNER RESEARCH INSTITUTE   (United States)

^h TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Myocardial infarction; Reinfarction; Revascularization; Thrombolysis; Trials

Indexed keywords

FIBRINOLYTIC AGENT; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; FIBRINOLYTIC THERAPY; HEART REINFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE REGRESSION; PRIORITY JOURNAL; REVASCULARIZATION; STROKE;

EID: 0035916268     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.103.7.954     Document Type: Article

References (18)

1. Frequency, significance, and cost of recurrent ischemia after thrombolytic therapy for acute myocardial infarction
2. Treatment of recurrent ischemia after thrombolysis and successful reperfusion for acute myocardial infarction: Effect on in-hospital mortality and left ventricular function
3. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction
4. Recurrent myocardial ischemia following thrombolytic therapy: Guidelines for practicing clinicians
5. Aspirin versus Coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: A prospective placebo-controlled angiographic study
6. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction
7. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction
8. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction
9. A pilot trial of recombinant desulfato-hirud compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial
10. Use of aortic counterpulsation to improve sustained coronary artery patency during acute myocardial infarction: Results of a randomized trial
11. Frequent reocclusion of patent infarct-related arteries between four weeks and one year: Effects of antiplatelet therapy
12. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
13. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomized trial
14. Adverse long-term effects of reocclusion after coronary thrombolysis
15. Intermittent, dose-related fluctuations of pain and ST elevation during infusion of recombinant tissue plasminogen activator during acute myocardial infarction
16. Repeated infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction and early recurrent myocardial ischemia
17. Evaluation of a QRS scoring system for estimating myocardial infarct size. VI: Identification of screening criteria for non-acute myocardial infarcts
18. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: Results from an international trial of 41 021 patients: GUSTO-I Investigators